Medulloblastoma
Symptoms, Doctors, Treatments, Advances & More

Medulloblastoma Overview

Save information for later
Sign Up

Learn About Medulloblastoma

View Main Condition: Brain Tumor

What is the definition of Medulloblastoma?
Medulloblastoma is a type of brain tumor that occurs in the cerebellum. The cerebellum is important for coordination, particularly balance and movement. Medulloblastoma often spreads through cerebrospinal fluid (CSF) to other areas of the brain and the spinal cord. Medulloblastoma is the most common childhood malignant brain tumor. Roughly 250-500 new cases of medulloblastoma are diagnosed each year. 
What are the causes of Medulloblastoma?
The cause of medulloblastomas is still unknown. However, medulloblastomas generally tend to be more common in children than adults. Males are also more likely to develop medulloblastomas than females.
What are the symptoms of Medulloblastoma?
Common symptoms of medulloblastoma include headaches, nausea, vomiting, fatigue, poor coordination, dizziness, or difficulty walking. If the medulloblastoma has spread to the spinal cord, symptoms may also include back pain and difficulty controlling bowel and bladder functions. 
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Medulloblastoma?
Treatment for glioma may include surgery, radiation therapy, and/or chemotherapy. Surgery to remove as much of the tumor as possible is generally the first step in treating medulloblastoma. However, if a tumor is located near a sensitive area in the brain, surgery may not be possible at all. Radiation therapy often follows surgery for the treatment of medulloblastoma. Radiation therapy involves the use of high-energy beams, including X-rays or protons, to destroy tumor cells. Chemotherapy involves the use of drugs, either taken orally or injected through a vein, to kill tumor cells. Chemotherapy is often used in combination with radiation therapy.
Who are the top Medulloblastoma Local Doctors?
Elite in Medulloblastoma
Dr. Amar Gajjar
Hematology | Oncology
Elite in Medulloblastoma
Dr. Amar Gajjar
Hematology | Oncology

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
901-595-2615
Languages Spoken:
English
See accepted insurances

Amar Gajjar is a Hematologist and an Oncologist in Memphis, Tennessee. Dr. Gajjar is rated as an Elite provider by MediFind in the treatment of Medulloblastoma. His top areas of expertise are Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, Diffuse Midline Glioma H3 K27M-Mutant, and Posterior Fossa Decompression.

Elite in Medulloblastoma
Andrey N. Korshunov
Elite in Medulloblastoma
Andrey N. Korshunov
Heidelberg, BW, DE 

Andrey Korshunov practices in Heidelberg, Germany. Mr. Korshunov is rated as an Elite expert by MediFind in the treatment of Medulloblastoma. His top areas of expertise are Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, and Ependymoma.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Medulloblastoma
Stefan M. Pfister
Elite in Medulloblastoma
Stefan M. Pfister
Heidelberg, BW, DE 

Stefan Pfister practices in Heidelberg, Germany. Mr. Pfister is rated as an Elite expert by MediFind in the treatment of Medulloblastoma. His top areas of expertise are Ependymoma, Medulloblastoma, Brain Tumor, Gliomatosis Cerebri, and Tissue Biopsy.

View All Doctors
How do I prevent Medulloblastoma?
There is no known way to prevent medulloblastomas. However, if you develop any symptoms common to a medulloblastoma, it is recommended to make an appointment with your doctor to be properly diagnosed.
What are the latest Medulloblastoma Clinical Trials?
SJiMB21: Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
SJiMB21: Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Phase: Phase 2

Summary: This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
Who is this study for: Patients with Medulloblastoma
Enrollment Status: Recruiting
Publish Date: February 03, 2026
Intervention Type: Drug
Study Drug: Difluoromethylornithine
Study Phase: Phase 2

Summary: Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.

View All Clinical Trials
What are some Advocacy Organizations?
keep-punching-brain-cancer

Keep Punching supports patients, healthcare providers, and researchers in their fight to prevent and eradicate brain cancer and minimize treatment-related side effects that may adversely impact function and comfort.